OverviewSuggest Edit

Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies biomarkers to match the right therapy. 
TypePublic
Founded2013
HQCambridge, US
Websitejouncetx.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2019)130(+3%)
Job Openings6
Share Price (Aug 2020)$5 (+5%)
Cybersecurity ratingBMore

Key People/Management at Jounce Therapeutics

Stephen Farrand

Stephen Farrand

Chief Technical Officer
Richard Murray

Richard Murray

Chief Executive Officer and President, Director
Robert Kamen

Robert Kamen

Director
Elizabeth Trehu

Elizabeth Trehu

Chief Medical Officer
Hugh Cole

Hugh Cole

Chief Business Officer and Head of Corporate Development
Kim Drapkin

Kim Drapkin

Chief Financial Officer
Show more

Jounce Therapeutics Office Locations

Jounce Therapeutics has an office in Cambridge
Cambridge, US (HQ)
780 Memorial Dr
Show all (1)

Jounce Therapeutics Financials and Metrics

Jounce Therapeutics Revenue

USD

Net income (Q1, 2020)

(26.4m)

EBIT (Q1, 2020)

(27.2m)

Market capitalization (10-Aug-2020)

171.6m

Closing stock price (10-Aug-2020)

5.0

Cash (31-Mar-2020)

75.0m

EV

115.7m
Jounce Therapeutics's current market capitalization is $171.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

23.1m26.4m27.9m

R&D expense

67.8m70.1m67.1m

Operating expense total

90.9m96.5m95.1m

EBIT

(19.2m)(31.3m)52.8m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

5.6m6.1m5.4m6.8m6.5m6.5m7.2m7.3m6.5m7.5m

R&D expense

15.0m17.2m17.1m18.2m18.5m16.8m17.3m18.1m15.1m19.6m

Operating expense total

20.5m23.3m22.5m25.0m25.0m23.3m24.5m25.5m21.6m27.2m

EBIT

(247.0k)(3.0m)(4.4m)(13.8m)(5.6m)(8.7m)(13.5m)(8.0m)97.8m(27.2m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

23.6m47.9m53.2m

Prepaid Expenses

19.9m2.3m4.9m

Current Assets

255.6m192.2m173.7m

PP&E

16.2m13.5m10.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(16.4m)(27.4m)56.8m

Accounts Payable

373.0k562.0k(944.0k)

Cash From Operating Activities

(90.7m)(63.6m)(30.1m)

Purchases of PP&E

(15.1m)(1.4m)(985.0k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

385.0k(3.0m)(7.1m)(13.0m)(17.7m)(25.3m)(12.4m)(19.4m)79.5m(26.4m)

Depreciation and Amortization

966.0k2.6m3.5m947.0k1.9m2.9m960.0k1.9m2.9m938.0k

Accounts Payable

1.1m323.0k1.3m2.3m201.0k231.0k771.0k(645.0k)167.0k1.4m

Cash From Operating Activities

(17.4m)(42.0m)(66.8m)(21.1m)(25.7m)(44.2m)(23.2m)(44.5m)(11.5m)(23.5m)
USDQ1, 2017

Financial Leverage

2 x
Show all financial metrics

Jounce Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Jounce Therapeutics Online and Social Media Presence

Embed Graph

Jounce Therapeutics News and Updates

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -

Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 -

Jounce Therapeutics Reports Third Quarter 2019 Financial Results

- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting -

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that safety and efficacy data for JTX-4014 and a clinical trial…

Jounce Therapeutics Reports First Quarter 2019 Financial Results

- New data from vopratelimab and JTX-8064 presented at AACR 2019 -

Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting

- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells -
Show more

Jounce Therapeutics Blogs

Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at the American Association for Cancer Research Virtual Annual Meeting

CAMBRIDGE, Mass. , May 15, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced two upcoming virtual poster presentations introducing the first

Jounce Therapeutics Reports First Quarter 2020 Financial Results

– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – – Ended the quarter with $148.6 million in cash, cash equivalents and investments – – Company to host

Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Content Import Wed, 04/29/2020 - 08:01 Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 …

Jounce Therapeutics to Present at Upcoming Investor Conferences in March

CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor

Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies

Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies Content Import Thu, 02/06/2020 - 08:01 …

Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors

Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors Content Import Thu, 01/23/2020 - 08:01 Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors January 23, 2020 at 8:00 AM EST This release is…
Show more

Jounce Therapeutics Frequently Asked Questions

  • When was Jounce Therapeutics founded?

    Jounce Therapeutics was founded in 2013.

  • Who are Jounce Therapeutics key executives?

    Jounce Therapeutics's key executives are Stephen Farrand, Richard Murray and Robert Kamen.

  • How many employees does Jounce Therapeutics have?

    Jounce Therapeutics has 130 employees.

  • Who are Jounce Therapeutics competitors?

    Competitors of Jounce Therapeutics include Aduro Biotech, Seattle Genetics and MetaStat.

  • Where is Jounce Therapeutics headquarters?

    Jounce Therapeutics headquarters is located at 780 Memorial Dr, Cambridge.

  • Where are Jounce Therapeutics offices?

    Jounce Therapeutics has an office in Cambridge.

  • How many offices does Jounce Therapeutics have?

    Jounce Therapeutics has 1 office.